Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, T-Cell, Cutaneous: full-pipeline trial registry
1 of 5 indexed Lymphoma, T-Cell, Cutaneous trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Lymphoma, T-Cell, Cutaneous: 5 US clinical trials tracked, 1 recruiting.
Lymphoma, T-Cell, Cutaneous is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Eisai, running 2 of these trials.
Enrollment posture brief
Registry condition lymphoma-t-cell-cutaneous
OPEN 1 | RECR 20% | LATE 2 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Lymphoma, T-Cell, Cutaneous lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, T-Cell, Cutaneous on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, T-Cell, Cutaneous is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphoma, T-Cell, Cutaneous research.
Eisai accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoma, T-Cell, Cutaneous enrolment sits around 170 participants.
Median target enrolment is 170 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Lymphoma, T-Cell, Cutaneous research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Tissue Repository: CTCL Collection Protocol
Columbia University
NCT02840747
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Innate Pharma
NCT03902184
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai
NCT00050999
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Eisai
NCT00211198
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Rhizen Pharmaceuticals
NCT02567656
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, T-Cell, Cutaneous records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, T-Cell, Cutaneous trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, T-Cell, Cutaneous page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lymphoma, T-Cell, Cutaneous trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eisai sponsors the most Lymphoma, T-Cell, Cutaneous trials on record, review their full trial history before evaluating a specific study. See Eisai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, T-Cell, Cutaneous condition card totals 5 registered trials; most-linked intervention RP6530; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.